Voutsadakis Ioannis A
Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S109-S114. doi: 10.1016/j.dsx.2016.12.018. Epub 2016 Dec 13.
Colorectal carcinoma is one of the most prevalent cancer types for both men and women. Prognosis of the disease is mostly defined by the stage. Localized disease has a better prognosis especially in earlier stages I and II. In addition most patients with more advanced localized stage III disease are expected to survive with a combination of surgery and adjuvant treatments. Progress in treatment of metastatic disease has led to median survivals exceeding 2 years and a minority of oligometastatic patients may survive even longer or be cured with multimodality therapy. Besides stage of the disease few prognostic factors are available to guide informative discussions with patients or guide therapeutic decisions. One area of research that may provide information in this direction is comorbidity conditions of the metabolic syndrome spectrum. Despite a significant body of literature investigating elements of the metabolic syndrome such as obesity and diabetes in isolation as risk and prognostic factors in colorectal cancer, a more restricted amount of research is dealing with the combination of these two factors as prognosticators of colorectal cancer. This paper will discuss published data on these factors and specifically their combination in the prognosis of colorectal cancer and will address some of their pathogenesis and therapy implications.
结直肠癌是男性和女性中最常见的癌症类型之一。该疾病的预后主要由分期决定。局限性疾病的预后较好,尤其是在早期的I期和II期。此外,大多数处于更晚期局限性III期疾病的患者有望通过手术和辅助治疗相结合而存活。转移性疾病治疗的进展已使中位生存期超过2年,少数寡转移患者甚至可能存活更长时间或通过多模式治疗治愈。除了疾病分期外,几乎没有预后因素可用于指导与患者的信息性讨论或指导治疗决策。一个可能在这个方向提供信息的研究领域是代谢综合征谱的合并症情况。尽管有大量文献单独研究代谢综合征的要素,如肥胖和糖尿病,作为结直肠癌的风险和预后因素,但针对这两个因素的组合作为结直肠癌预后指标的研究较少。本文将讨论关于这些因素的已发表数据,特别是它们在结直肠癌预后中的组合,并将探讨它们的一些发病机制和治疗意义。